Funding
Series B · Biotech

NovaGo raises CHF24m Series B for spinal-cord-injury trial

Neurimmune and Pureos Bioventures led the financing for a 120-patient proof-of-concept study.

Updated Oct 18, 2026By RoundOS Funding desk

The financing will advance NovaGo’s lead anti-Nogo-A programme into a randomised, double-blind study in acute spinal-cord injury. The antibody targets a protein that limits nerve-fibre regeneration and neuroplasticity, with the aim of improving functional recovery.

Swiss Paraplegic Foundation and Wings for Life are providing separate non-dilutive support for the programme. NovaGo is also developing treatments for stroke and secondary progressive multiple sclerosis.

Use of funds

Advance the lead program into a proof-of-concept study in acute spinal cord injury

Funding history

Series B · This roundCHF 24M

Sources

  1. NovaGo Therapeutics closes CHF 24 million Series B financingprnewswire.com · Sep 2, 2026
  2. Tech.eu Funding Explorer: NovaGo Therapeutics funding record (2026-09-02)funding.tech.eu

Similar rounds

All Biotech rounds →
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026
SEGNOS

SEGNOS develops magnetic-particle materials and diagnostic technologies for blood testing.

UndisclosedPre-Series A · Oct 22, 2026

Related